The infections caused by Salmonella remain a significant public health problem throughout the world. b-Lactams and fluoroquinolones are generally used to treat invasive Salmonella infections, but emergence and spread of antibiotic-resistant strains are being increasingly notified in many countries. In particular, detection of extendedspectrum b-lactamases (ESBLs) in Salmonella spp. is a newly emerging threat worldwide. This study was carried out to characterize b-lactamase-producing Salmonella strains identified in Tehran, Iran. Over the 2-year period from 2007 to 2008, 6 of 136 Salmonella isolates recovered from pediatrics patients, including three Salmonella enterica serotypes Enteritidis (S. Enteritidis) and three S. Infantis, showed an ESBL-positive phenotype. Polymerase chain reaction and sequencing were used to identify the genetic determinants responsible for ESBL phenotypes. The Salmonella isolates were also compared by pulsed-field gel electrophoresis. All ESBL-producing strains, but one, carried the bla CTX-M-15 gene. Moreover, three of four strains that proved to be positive for a bla TEM gene were producing a TEM-1 b-lactamase. Two strains of S. Infantis tested positive for a previously unidentified CTX-M and TEM ESBL, respectively. All ESBL-producing strains carried the insertion sequence ISEcp1 gene. Except for one strain of serotype Infantis, all strains were able to transfer the ESBL determinants by conjugation. Distinct, but closely related, pulsed-field gel electrophoresis patterns were observed among the strains belonging to both serotypes. This study reports for the first time the emergence and characterization of ESBL-producing S. Enteritidis and Infantis strains in Iran.
Introduction
T he infections caused by Salmonella remain a significant public health problem throughout the world (Su et al., 2005) . Salmonella species causing nontyphoidal disease are among the most common enteric bacterial pathogens isolated from children (Li et al., 2005) . These infections commonly cause self-limiting gastroenteritis, but severe infections, including bacteremia and meningitis, have also been reported (Parry, 2003) .
Increasing occurrence of antimicrobial resistance in both typhoidal and nontyphoidal salmonellae is a serious public health problem. Cephalosporins are major antimicrobials used for treatment of serious infections caused by Salmonella (Rotimi et al., 2008) . Moreover, third-generation cephalosporins are first-choice drugs for treatment of patients with nontyphoidal Salmonella infections (Egorova et al., 2008) . However, their effectiveness is being compromised by the emergence of extended-spectrum b-lactamases (ESBLs) (Rotimi et al., 2008) . This is of particular concern for the treatment of salmonellosis in children, because fluoroquinolones could not be used in this age group (Yates and Amyes, 2005) .
Cephalosporin-resistant Salmonella strains have been recognized since 1988 and are increasing in prevalence worldwide. This resistance in Salmonella may be encoded by an increasing number of different ESBLs: most are derivatives of TEM and SHV b-lactamase families, whereas other groups, such as CTX-M, PER, and KPC, have been described in these last years (Tzouvelekis et al., 2000; Winokur et al., 2000; Mulvey et al., 2003) . Moreover, genes encoding AmpC b-lactamases, that have historically been reported to be chromosomally located in some genera of the family Enterobacteriaceae, have been more recently described to disseminate within various species as plasmid-borne and confer high-level resistance to b-lactams (Qin et al., 2008) .
Here we report the characterization of the first ESBLproducing nontyphoidal Salmonella strains isolated in Tehran, Iran, in the years 2007 and 2008.
Methods

Bacterial strains
The study included all Salmonella isolates recovered from pediatric patients aged less than 12 years and admitted to a major children hospital in Tehran, Iran, in the years 2007 and 2008. A single specimen was obtained from each patient and collected on the day of admission at the hospital. The isolates that had been identified as Salmonella by the conventional biochemical methods were serotyped by slide agglutination with specific antisera (Staten Serum Institut, Copenhagen, Denmark) at the Centre for Enteric Pathogens of Southern Italy, University of Palermo, Italy (Bopp et al., 1999) .
Disk diffusion tests were performed according to the Clinical and Laboratory Standards Institute's (formerly National Committee for Clinical Laboratory Standards) recommendations (CLSI, 2005) using disks (Oxoid, Hampshire, England) impregnated with ampicillin (10 mg), amoxicillinclavulanic acid (AMC, 20-10 mg), aztreonam (30 mg), cefepime (30 mg), cephalothin (30 mg), cefotaxime (CX, 30 mg), ceftizoxime (30 mg), ceftriaxone (CR, 30 mg), ceftazidime (CZ, 30 mg), cefoxitin (FOX, 30 mg), ciprofloxacin (5 mg), chloramphenicol (30 mg), streptomycin (10 mg), kanamycin (10 mg), gentamicin (10 mg), imipenem (10 mg), nalidixic acid (30 mg), piperacillin (100 mg), ticarcillin (75 mg), trimethoprim-sulfamethoxazole (1.25=23.75 mg), and tetracycline (30 mg). Minimum inhibitory concentration (MIC) values of AMC, CX, CR, and CZ were determined by the agar dilution method (CLSI, 2006) . For quality control of the culture media and antimicrobial drugs under study, Escherichia coli ATCC 25922 and in-house known ESBL-positive E. coli, Klebsiella pneumoniae, AmpC-positive Enterobacter cloacae, and ESBL-negative strains were tested under the same conditions.
Detection and identification of b-lactamases
ESBL screening was performed by the use of a double disk synergy test ( Jarlier et al., 1988) . The combination disk method based on the inhibitory effect of clavulanic acid was also used according to the Clinical and Laboratory Standards Institute's criteria (CLSI, 2005) .
The presence and characterization of ESBL genes as well as their genetic environment in the six ESBL-producing Salmonella enterica isolates were investigated by polymerase chain reaction (PCR) and sequencing. PCR amplification of bla genes, including bla TEM , bla SHV , and bla CTX-M , was performed with Go-Taq DNA polymerase (Promega, Madison, WI) using primers listed by Kiratisin et al. (2008) . Detection of ISEcp1 was performed for all isolates carrying bla CTX-M by PCR using primers and conditions described previously (Kiratisin et al., 2008) . All PCR amplicons were verified by agarose gel electrophoresis after staining the gels with ethidium bromide.
Purifications of PCR amplicons were carried out by using a QIAquick PCR Purification Kit (Qiagen GmbH, Hilden, Germany). PCR products of bla genes were subjected to bidirectional nucleotide sequencing using PCR primers to determine their molecular types. The nucleotide sequences and the deduced protein sequences were analyzed with the BLAST and Clustal W programs (multiple sequence alignment, pairwise comparisons of sequences, and dendrograms) (Thompson et al., 1994; Altschul et al., 1997) .
Phenotypic detection of AmpC enzymes was performed using FOX (30 mg) and E. coli ATCC 25922 according to the method described by Shahid et al. (2004) . Bacterial isolates were directly screened by spot inoculation of the test organisms near a FOX disk.
Conjugation assay
To demonstrate that bla genes detected by PCR were located on plasmids, resistance transfer experiments using a broth mating method were performed for all six isolates (Gray et al., 2006) . Rifampicin-resistant E. coli K12J5 was used as the recipient. After 24 h, the mating mixture was centrifuged and the supernatant removed to eliminate cell-free b-lactamases. The mixture was then resuspended in saline and plated onto MacConkey agar (Oxoid, Basingstoke, UK) supplemented with CX (2 mg=mL) and rifampicin (150 mg=mL). Antimicrobial susceptibility, a confirmatory test for ESBL and AmpC phenotypes, and PCR detection for ESBL genes were performed on transconjugants using the aforementioned procedures.
Pulsed-field gel electrophoresis
For molecular typing, chromosomal DNAs of ESBLproducing Salmonella strains were subjected to pulsed-field gel electrophoresis (PFGE) analysis using a CHEF Mapper XA apparatus (Bio-Rad Laboratories, Hercules, CA). Agarose plugs containing bacterial DNA were prepared and processed for PFGE as described elsewhere (Ranjbar et al., 2007 (Ranjbar et al., , 2008 . Restriction analysis of chromosomal DNA with XbaI (New England BioLabs, Beverly, MA) was performed, and separation of DNA was carried out by using 1% pulsed-field gel agarose (SeaKem Gold agarose; Cambrex Bio Science, Rockland, ME). DNA banding patterns were visually compared and interpreted according to the criteria suggested by Tenover et al. (1995) .
Results
Six of the 136 pediatric S. enterica isolates identified in Tehran, Iran, during the years 2007 and 2008 showed an ESBL-positive phenotype. Three strains were attributed with serotype Enteritidis and three with serotype Infantis.
The resistance patterns of the six strains are illustrated in Table 1 . All isolates were resistant to AMC with a MIC range of 128-256 mg=mL, CX with a MIC range of 128-256 mg=mL, CR with a MIC range of 128-256 mg=mL, and CZ with a MIC range of 64-128 mg=mL. All were susceptible to imipenem and ciprofloxacin.
The six isolates were subjected to PCR experiments to detect ESBL genes, including bla TEM , bla SHV , and bla CTX-M . bla CTX-M sequences were detected in all Salmonella strains, whereas bla TEM in four isolates, two Enteritidis and two Infantis, respectively (Table 1) . None of the Salmonella isolates was positive for bla SHV . Amplification with primer ISEcp1 yielded a PCR product of 615 bp in all isolates. Amplification 2 RANJBAR ET AL.
with primer ISEcp1 and an internal bla CTX-M primer yielded a PCR product of &1000 bp. DNA sequencing revealed that bla CTX-M from five of the six Salmonella isolates was identical and encoded for bla CTX-M15 . A novel CTX-M nucleotide sequence (GenBank accession no. FJ873739), designated bla CTX-M 88 , was detected in the S. Infantis 120 strain. The deduced amino acid sequence (291 residues) of the novel CTX-M compared with other related enzymes revealed that it was similar to CTX-M-15, except for the single amino acid substitution of histidine in place of arginine at position 277. Sequence analysis of bla TEM detected bla TEM-1 in three of four strains of Salmonella. A novel TEM nucleotide sequence, designated bla TEM-169 , was found in the S. Infantis 149 strain (GenBank accession no. FJ873740). The amino acid sequence (289 residues) of the novel TEM compared with other related enzymes revealed that it differed from the parental enzyme TEM-1 for the amino acid substitutions of leucine in place of methionine at position 69 and glycine in place of tryptophan at position 165 (Table 2) . These amino acid substitutions are consistent with the inclusion of the novel TEM in the groups of the TEM-type enzymes resistant to inhibitors (IRT) (4).
All Salmonella strains and the respective transconjugants were tested negative for AmpC b-lactamases by the spotinoculation method. All the results were replicated in duplicate experiments. No further investigation was conducted for detection of these enzymes.
Based on the conjugation assay, all strains, but the S. Infantis strains 120, were able to transfer the bla genes to transconjugants, suggesting that they were plasmid mediated. The MIC range of the transconjugants for CX, CR, and CZ was 64-128, 128-256, and 16-32 mg=mL, respectively. Only S. Infantis 149 proved to be able to horizontally transfer resistance to AMC; indeed, the transconjugants demonstrated reduced susceptibility (MIC, 16 mg=mL) compared with the recipient strain (MIC, 1 mg=mL).
The PFGE banding patterns of the three ESBL S. Enteritidis and S. Infantis isolates, respectively, were distinguishable ( Fig. 1) and, hence, likely clonally unrelated.
Discussion
CTX-M enzymes emerged *20 years ago, shortly following the introduction in the clinical practice of CX. Since then, the dissemination of these enzymes is steadily increasing worldwide and today it involves both hospital-acquired and community infections (Kiratisin et al., 2007) . In the past, CTX-M ESBL enzymes have been found almost exclusively in E. coli and Klebsiella spp., in association with multiple drug resistance. However, more recently, ESBL-producing Salmonella isolates from human source have been noticed through an increasing number of countries worldwide (Su et al., 2005; Egorova et al., 2008; Rotimi et al., 2008; Riañ o et al., 2009) . Since 1990, the effectiveness of combinations of hydrolyzable penicillins with a b-lactamase inhibitor, such as clavulanic acid or sulbactam, has been also compromised by the emergence of the mutant TEM-type b-lactamases, collectively designed as IRT b-lactamases (Chaïbi et al., 1999) . Moreover, incidence of plasmid-mediated AmpC-producing strains, driven by the emergence of the plasmid-borne bla CMY-2 gene, has sharply increased in recent years in both hospital and community settings (Qin et al., 2008) .
In this study, CTX-M and TEM ESBLs have been found in six isolates of serotypes Enteritidis and Infantis, the two most ESBL, extended-spectrum b-lactamase; PFGE, pulsed-field gel electrophoresis; AMP, ampicillin; AMC, amoxicillin-clavulanic acid; AT, aztreonam; CF, cephalothin; CR, ceftriaxone; CX, cefotaxime; CZ, ceftazidime; CT, ceftizoxime; FE, cefepime; K, kanamycin; NAL, nalidixic acid; PIP, piperacillin; SXT, sulfamethoxazole-trimethoprim; TIC, ticarcillin; S, streptomycin; TET, tetracycline. The amino acid that will be substituted is indicated when a point mutation generates an amino acid substitution compared with the sequence of TEM-1.
IRT, inhibitor-resistant TEM-type enzymes.
prevalent serotypes from pediatric cases of salmonellosis in Tehran, Iran (data not published). Prevalence of ESBLproducing Salmonella was 4.2% with a lower proportion than that of about 17% attributable to isolates from Kuwait and United Arab Emirates (Rotimi et al., 2008) . However, our prevalence was higher than the prevalence of 1.5% in Taiwan, 1.9% in the United States, 2.4% in Latin America, and 0.8% in Europe (Dunne et al., 2000; Winokur et al., 2000; Li et al., 2005) . The pattern of ESBL production was also consistent with data of Rotimi et al. (2008) from Kuwait and United Arab Emirates. However, it is interesting to outline the presence within the ESBLs identified in this study of two novel ESBLs, CTX-M-88 and TEM-169, both confirming the anticipated continuous emergence of mutants under the selective pressure of the use of oxymino cephalosporins and b-lactamase inhibitors. The ISEcp1 insertion sequence that has been implicated in the expression and mobilization of the bla CTX-M genes has been also detected in the six isolates under study (Eckert et al., 2004) . The finding of the bla CTX-M genes in Salmonella in association with ISEcp1 is of serious concern, because of the propensity of the latter to facilitate the spread of resistance. Our finding is particularly worrying as the treatment of Salmonella systemic infections in infants and children closely depends on the use of third-generation cephalosporins.
The S. Enteritidis and Infantis strains under study proved to be negative to a phenotypic test for detection of AmpC b-lactamases. However, with the exception of the Infantis strain bearing the plasmid-borne IRT bla TEM-169 , the apparently chromosome-located resistance to AMC in the remaining five isolates could be supposedly associated to an AmpC-like genetic determinant. Epidemiological data suggest the opportunity for considering AmpC enzymes when screening for b-lactamases by phenotypic and PCR-based techniques in isolates belonging to the family of Enterobacteriaceae.
Molecular typing of isolates demonstrated some degree of genetic diversity that has to be considered in the light of the worldwide clonal dissemination of some serotypes such as Enteritidis. The relative genomic heterogeneity within the isolates along with the absence of time-space clustering of their isolation and allocation of their drug resistance genes on plasmid DNA suggests horizontal gene transfer among strains rather than spread of specific clones.
The results of our surveillance study would describe the involvement of Iran in an epidemic, the antimicrobial drug resistance that is increasingly compromising the usefulness of the b-lactam antibiotics and other previously life-saving antibacterial drugs. Indeed, because ESBL-producing strain prevalence greatly varies between different sites and in the same site over time, regional and local estimates are most useful to epidemiological assessment of such a public health threat, but to clinical decision-making also (Winokur et al., 2001; Pfaller and Segreti, 2006) .
Proper detection of b-lactamases and corresponding treatment strategies are of paramount importance in curtailing this growing epidemic. Prevention and control strategies should be urgently implemented to stop further spreading of these strains.
